and wherein in any group consisting of or containing a hydrocarbyl moiety, the hydrocarbyl moiety is a hydrocarbon group optionally containing one or more single, double or triple carbon-carbon bonds or combinations thereof.

In one embodiment, the invention provides a compound of the formula (0):



(0)

or a salt, N-oxide or tautomer thereof, wherein:

T^1 and T^2 are N;

R^1 is selected from hydrogen, fluorine, C_{1-4} hydrocarbyl and C_{1-4} hydrocarbyloxy;

R^2 is selected from hydrogen, fluorine, C_{1-4} hydrocarbyl and C_{1-4} hydrocarbyloxy;

R^3 is selected from hydrogen, methyl, fluorine, chlorine and bromine;

one of M^1 and M^2 is a group R^4 selected from hydrogen, methyl, fluorine, chlorine and bromine; and the other of M^1 and M^2 is a moiety $-A-R^7$;

R^5 is selected from hydrogen, cyano, C_{1-3} alkyl, cyclopropyl, and chlorine;

R^6 is selected from hydrogen, fluorine, C_{1-4} alkyl; and C_{1-4} alkoxy optionally substituted with NR^dR^e wherein R^d and R^e are the same or different and each is selected from hydrogen and C_{1-4} alkyl, or NR^dR^e forms a 4 to 7 membered saturated heterocyclic ring optionally containing a second heteroatom ring member selected from N, O and S and oxidized forms of S, the saturated heterocyclic ring being optionally substituted with one or more substituents selected from oxo, methyl, hydroxy and fluorine;

A is selected from:

(i) a bond;

(ii) $(CR^pR^q)_x$ wherein R^p and R^q are each independently hydrogen or methyl and x is 1 to 4;

(iii) an oxygen atom;

(iv) a group NR^r wherein R^r is hydrogen or methyl; and

(v) a saturated chain of 2 to 10 chain members in length containing at least one carbon atom chain member, at least one heteroatom chain member selected from nitrogen and oxygen, and optionally one or more further carbon atom chain

members and/or heteroatom chain members selected from nitrogen, oxygen, sulphur, sulphinyl and sulphonyl; the saturated chain being optionally substituted with one or more substituents selected from =O, C_{1-4} hydrocarbyl, fluoro-C_{1-4} hydrocarbyl, hydroxy-C_{1-4} hydrocarbyl, C_{1-2}-alkoxy-C_{1-4} hydrocarbyl, and fluorine wherein two hydrocarbyl substituents on the same carbon atom may optionally link to form a ring of three to five ring members;

R^7 is a group Cyc^1 wherein(i) when A is a bond, Cyc^1 is a non-aromatic carbocyclic or heterocyclic group; or (ii) Cyc^1 is a heterocyclic non-aromatic group of 4 to 7 ring members of which 1 to 2 are selected from O, N and S and oxidized forms thereof, the heterocyclic non-aromatic group being optionally substituted with one or more substituents R^8;

R^8 is selected from:

- halogen;
- oxo;
- cyano;
- nitro;
- a carbocyclic or heterocyclic group having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R^9; and
- a group R^a-R^b;

R^a is a bond, O, CO, $X^1C(X^2)$, $C(X^2)X^1$, $X^1C(X^2)X^1$, S, SO, SO_2, NR^c, SO_2NR^c or NR^cSO_2;

R^b is selected from:

- hydrogen;
- a carbocyclic or heterocyclic group having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R^9;
- an acyclic C_{1-12} hydrocarbyl group optionally substituted with one or more substituents selected from hydroxy; oxo; halogen; cyano; nitro; carboxy; amino; mono- or di-C_{1-8} non-aromatic hydrocarbylamino; and carbocyclic or heterocyclic groups having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R^9; wherein one or more but not all of the carbon atoms of the acyclic

- C_{1-12} hydrocarbyl group may optionally be replaced by O, S, SO, SO_2, NR^c, $X^1C(X^2)$, $C(X^2)X^1$ or $X^1C(X^2)X^1$;

R^c is selected from:

- hydrogen;
- a carbocyclic or heterocyclic group having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R^9;
- an acyclic C_{1-12} hydrocarbyl group optionally substituted with one or more substituents selected from hydroxy; oxo; halogen; cyano; nitro; carboxy; amino; mono- or di-C_{1-8} non-aromatic hydrocarbylamino; and carbocyclic or heterocyclic groups having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R^9; wherein one or more but not all of the carbon atoms of the acyclic C_{1-12} hydrocarbyl group may optionally be replaced by O, S, SO, SO_2, NH, N-C_{1-4} alkyl, C(O)O, OC(O), NH(CO), C(O)NH, NH(CO)NH, N(C_{1-4} alkyl)C(O), C(O)N(C_{1-4} alkyl)

X^1 is O, S or NR^c; and

X^2 is =O, =S or =NR^c;

wherein R^9 is selected from R^8 provided that when the substituents R^9 contain a carbocyclic or heterocyclic group, the said carbocyclic or heterocyclic group is unsubstituted or substituted with one or more substituents R^{10};

R^{10} is selected from halogen, oxo, cyano, and an acyclic C_{1-6} hydrocarbyl group optionally substituted with one or more substituents selected from hydroxy; oxo; halogen; cyano; carboxy; amino; mono- or di-C_{1-2} alkylamino; wherein one but not all of the carbon atoms of the acyclic C_{1-6} hydrocarbyl group may optionally be replaced by O, S, SO, SO_2, NH or NMe;

R^{11} is selected from amino, Hyd^1, NH-Hyd^1, N(Hyd^1)$_2$; and Cyc^1;

Hyd^1 is a non-aromatic C_{1-6} hydrocarbyl group optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, amino and Cyc^1, wherein one or two of the carbon atoms of the non-aromatic C_{1-6} hydrocarbyl group may optionally be replaced by O, NH, N-Hyd^2, C(=O), S, SO or SO_2, provided that at least one carbon atom of the hydrocarbyl group remains;

Hyd^2 is a C_{1-4} hydrocarbyl group;

and wherein in any group consisting of or containing a hydrocarbyl moiety, the hydrocarbyl moiety is a hydrocarbon group optionally containing one or more single, double or triple carbon-carbon bonds or combinations thereof.

In one embodiment, the invention provides a compound as described herein having the formula (1):



(1)

or a salt, N-oxide or tautomer thereof, wherein:

A is selected from:

(i) a bond; and

(ii) a saturated chain of 2 to 10 chain members in length containing at least one carbon atom chain member, at least one heteroatom chain member selected from nitrogen and oxygen, and optionally one or more further carbon atom chain members and/or heteroatom chain members selected from nitrogen, oxygen, sulphur, sulphinyl and sulphonyl; the saturated chain being optionally substituted with one or more substituents selected from =O, C_{1-4} hydrocarbyl and fluorine wherein two hydrocarbyl substituents on the same carbon atom may optionally link to form a ring of three to five ring members;

R^1 is selected from hydrogen, fluorine, C_{1-4} hydrocarbyl and C_{1-4} hydrocarbyloxy;

R^2 is selected from hydrogen, fluorine, C_{1-4} hydrocarbyl and C_{1-4} hydrocarbyloxy;

R^3 is selected from hydrogen, methyl, chlorine and bromine;

R^4 is selected from hydrogen, methyl, chlorine and bromine;

R^5 is selected from hydrogen, cyano and methyl;

R^6 is selected from hydrogen, C_{1-4} alkyl; and C_{1-4} alkoxy optionally substituted with NR^dR^e where R^d and R^e are the same or different and each is selected from hydrogen and C_{1-4} alkyl, or NR^dR^e forms a 4 to 7 membered saturated heterocyclic ring optionally containing a second heteroatom ring member selected from N, O and S and oxidized forms of S, the saturated heterocyclic ring being optionally substituted with one or more substituents selected from oxo, methyl, hydroxy and fluorine;

R^8 is selected from:

- halogen;
- oxo;
- cyano;
- nitro;
- a carbocyclic or heterocyclic group having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R^9; and
- a group R^a-R^b;

R^a is a bond, O, CO, $X^1C(X^2)$, $C(X^2)X^1$, $X^1C(X^2)X^1$, S, SO, SO_2, NR^c, SO_2NR^c or NR^cSO_2;

R^b is:

- hydrogen;
- a carbocyclic or heterocyclic group having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R^9;
- an acyclic C_{1-12} hydrocarbyl group optionally substituted with one or more substituents selected from hydroxy; oxo; halogen; cyano; nitro; carboxy; amino; mono- or di-C_{1-8} non-aromatic hydrocarbylamino; and carbocyclic or heterocyclic groups having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R^9; wherein one or more but not all of the carbon atoms of the acyclic C_{1-12} hydrocarbyl group may optionally be replaced by O, S, SO, SO_2, NR^c, $X^1C(X^2)$, $C(X^2)X^1$ or $X^1C(X^2)X^1$;

R^c is:

- hydrogen;
- a carbocyclic or heterocyclic group having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R^9;
- an acyclic C_{1-12} hydrocarbyl group optionally substituted with one or more substituents selected from hydroxy; oxo; halogen; cyano; nitro; carboxy; amino; mono- or di-C_{1-8} non-aromatic hydrocarbylamino; and carbocyclic or heterocyclic groups having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom

- ring members selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R^9; wherein one or more but not all of the carbon atoms of the acyclic C_{1-12} hydrocarbyl group may optionally be replaced by O, S, SO, SO_2, NH, N-C_{1-4} alkyl, C(O)O, OC(O), NH(CO), C(O)NH, NH(CO)NH, N(C_{1-4} alkyl)C(O), C(O)N(C_{1-4} alkyl)

X^1 is O, S or NR^c; and

X^2 is =O, =S or =NR^c;

wherein R^9 is selected from R^8 provided that when the substituents R^9 contain a carbocyclic or heterocyclic group, the said carbocyclic or heterocyclic group is unsubstituted or substituted with one or more substituents R^{10};

R^{10} is selected from halogen, oxo, cyano, and an acyclic C_{1-6} hydrocarbyl group optionally substituted with one or more substituents selected from hydroxy; oxo; halogen; cyano;carboxy; amino; mono- or di-C_{1-2} alkylamino; wherein one but not all of the carbon atoms of the acyclic C_{1-6} hydrocarbyl group may optionally be replaced by O, S, SO, SO_2, NH or NMe;

R^{11} is selected from amino, Hyd^1, NH-Hyd^1, N(Hyd^1)$_2$; and Cyc^1;

Hyd^1 is a non-aromatic C_{1-6} hydrocarbyl group optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, amino and Cyc^1, wherein one or two of the carbon atoms of the non-aromatic C_{1-6} hydrocarbyl group may optionally be replaced by O, NH, N-Hyd^2, C(=O), S, SO or SO_2, provided that at least one carbon atom of the hydrocarbyl group remains;

Hyd^2 is a C_{1-4} hydrocarbyl group;

and wherein in any group consisting of or containing a hydrocarbyl moiety, the hydrocarbyl moiety is a hydrocarbon group optionally containing one or more single, double or triple carbon-carbon bonds or combinations thereof.

In one embodiment, the invention provides a pharmaceutical composition comprising a compound as described herein and a pharmaceutically acceptable excipient.

In one embodiment, the invention provides a combination comprising a compound as described herein and another chemotherapeutic agent.

In one embodiment, the invention provides use of a compound as described herein, in combination with another chemotherapeutic agent in the manufacture of a medicament for the treatment of a proliferative disease.

In one embodiment, the invention provides a combination comprising a compound as disclosed herein and another chemotherapeutic agent, for example an anticancer drug.

In one embodiment, the invention provides the use of a compound as disclosed herein, optionally in combination with another chemotherapeutic agent or radiotherapy in the manufacture of a medicament for the treatment of a proliferative disease.

1. A compound of the formula (0):



(0)

or a salt, N-oxide or tautomer thereof, wherein:

T^1 and T^2 are N;

R^1 is selected from hydrogen, fluorine, C_{1-4} hydrocarbyl and C_{1-4} hydrocarbyloxy;

R^2 is selected from hydrogen, fluorine, C_{1-4} hydrocarbyl and C_{1-4} hydrocarbyloxy;

R^3 is selected from hydrogen, methyl, fluorine, chlorine and bromine;

one of M^1 and M^2 is a group R^4 selected from hydrogen, methyl, fluorine, chlorine and bromine; and the other of M^1 and M^2 is a moiety $-A-R^7$;

R^5 is selected from hydrogen, cyano, C_{1-3} alkyl, cyclopropyl, and chlorine;

R^6 is selected from hydrogen, fluorine, C_{1-4} alkyl; and C_{1-4} alkoxy optionally substituted with NR^dR^e wherein R^d and R^e are the same or different and each is selected from hydrogen and C_{1-4} alkyl, or NR^dR^e forms a 4 to 7 membered saturated heterocyclic ring optionally containing a second heteroatom ring member selected from N, O and S and oxidized forms of S, the saturated heterocyclic ring being optionally substituted with one or more substituents selected from oxo, methyl, hydroxy and fluorine;

A is selected from:

(i) a bond;

(ii) $(CR^pR^q)_x$ wherein R^p and R^q are each independently hydrogen or methyl and x is 1 to 4;

(iii) an oxygen atom;

(iv) a group NR^r wherein R^r is hydrogen or methyl; and

(v) a saturated chain of 2 to 10 chain members in length containing at least one carbon atom chain member, at least one heteroatom chain member selected from nitrogen and oxygen, and optionally one or more further carbon atom chain members and/or heteroatom chain members selected from nitrogen, oxygen, sulphur, sulphinyl

and sulphonyl; the saturated chain being optionally substituted with one or more substituents selected from =O, C_{1-4} hydrocarbyl, fluoro-C_{1-4} hydrocarbyl, hydroxy-C_{1-4} hydrocarbyl, C_{1-2}-alkoxy-C_{1-4} hydrocarbyl, and fluorine wherein two hydrocarbyl substituents on the same carbon atom may optionally link to form a ring of three to five ring members;

R^7 is a group Cyc^1 wherein(i) when A is a bond, Cyc^1 is a non-aromatic carbocyclic or heterocyclic group; or (ii) Cyc^1 is a heterocyclic non-aromatic group of 4 to 7 ring members of which 1 to 2 are selected from O, N and S and oxidized forms thereof, the heterocyclic non-aromatic group being optionally substituted with one or more substituents R^8;

R^8 is selected from:

- halogen;
- oxo;
- cyano;
- nitro;
- a carbocyclic or heterocyclic group having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R^9; and
- a group R^a-R^b;

R^a is a bond, O, CO, $X^1C(X^2)$, $C(X^2)X^1$, $X^1C(X^2)X^1$, S, SO, SO_2, NR^c, SO_2NR^c or NR^cSO_2;

R^b is selected from:

- hydrogen;
- a carbocyclic or heterocyclic group having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R^9;
- an acyclic C_{1-12} hydrocarbyl group optionally substituted with one or more substituents selected from hydroxy; oxo; halogen; cyano; nitro; carboxy; amino; mono- or di-C_{1-8} non-aromatic hydrocarbylamino; and carbocyclic or heterocyclic groups having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R^9; wherein one or more but not all of the carbon atoms of the acyclic C_{1-12} hydrocarbyl

group may optionally be replaced by O, S, SO, SO_2, NR^c, $X^1C(X^2)$, $C(X^2)X^1$ or $X^1C(X^2)X^1$;

R^c is selected from:

- hydrogen;
- a carbocyclic or heterocyclic group having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R^9;
- an acyclic C_{1-12} hydrocarbyl group optionally substituted with one or more substituents selected from hydroxy; oxo; halogen; cyano; nitro; carboxy; amino; mono- or di-C_{1-8} non-aromatic hydrocarbylamino; and carbocyclic or heterocyclic groups having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R^9; wherein one or more but not all of the carbon atoms of the acyclic C_{1-12} hydrocarbyl group may optionally be replaced by O, S, SO, SO_2, NH, N-C_{1-4} alkyl, C(O)O, OC(O), NH(CO), C(O)NH, NH(CO)NH, N(C_{1-4} alkyl)C(O), C(O)N(C_{1-4} alkyl)

X^1 is O, S or NR^c; and

X^2 is =O, =S or =NR^c;

wherein R^9 is selected from R^8 provided that when the substituents R^9 contain a carbocyclic or heterocyclic group, the said carbocyclic or heterocyclic group is unsubstituted or substituted with one or more substituents R^{10};

R^{10} is selected from halogen, oxo, cyano, and an acyclic C_{1-6} hydrocarbyl group optionally substituted with one or more substituents selected from hydroxy; oxo; halogen; cyano; carboxy; amino; mono- or di-C_{1-2} alkylamino; wherein one but not all of the carbon atoms of the acyclic C_{1-6} hydrocarbyl group may optionally be replaced by O, S, SO, SO_2, NH or NMe;

R^{11} is selected from amino, Hyd^1, NH-Hyd^1, N(Hyd^1)$_2$; and Cyc^1;

Hyd^1 is a non-aromatic C_{1-6} hydrocarbyl group optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, amino and Cyc^1, wherein one or two of the carbon atoms of the non-aromatic C_{1-6} hydrocarbyl group may optionally be replaced by O, NH, N-Hyd^2, C(=O), S, SO or SO_2, provided that at least one carbon atom of the hydrocarbyl group remains;

Hyd^2 is a C_{1-4} hydrocarbyl group;

and wherein in any group consisting of or containing a hydrocarbyl moiety, the hydrocarbyl moiety is a hydrocarbon group optionally containing one or more single, double or triple carbon-carbon bonds or combinations thereof.

2. A compound according to claim 1 having the formula (1):



(1)

or a salt, N-oxide or tautomer thereof, wherein:

A is selected from:

(i) a bond; and

(ii) a saturated chain of 2 to 10 chain members in length containing at least one carbon atom chain member, at least one heteroatom chain member selected from nitrogen and oxygen, and optionally one or more further carbon atom chain members and/or heteroatom chain members selected from nitrogen, oxygen, sulphur, sulphinyl and sulphonyl; the saturated chain being optionally substituted with one or more substituents selected from =O, C_{1-4} hydrocarbyl and fluorine wherein two hydrocarbyl substituents on the same carbon atom may optionally link to form a ring of three to five ring members;

R^1 is selected from hydrogen, fluorine, C_{1-4} hydrocarbyl and C_{1-4} hydrocarbyloxy;

R^2 is selected from hydrogen, fluorine, C_{1-4} hydrocarbyl and C_{1-4} hydrocarbyloxy;

R^3 is selected from hydrogen, methyl, chlorine and bromine;

R^4 is selected from hydrogen, methyl, chlorine and bromine;

R^5 is selected from hydrogen, cyano and methyl;

R^6 is selected from hydrogen, C_{1-4} alkyl; and C_{1-4} alkoxy optionally substituted with NR^dR^e where R^d and R^e are the same or different and each is selected from hydrogen and C_{1-4} alkyl, or NR^dR^e forms a 4 to 7 membered saturated heterocyclic ring optionally containing a second heteroatom ring member selected from N, O and S and oxidized forms of S, the saturated

heterocyclic ring being optionally substituted with one or more substituents selected from oxo, methyl, hydroxy and fluorine;

R^8 is selected from:

- halogen;
- oxo;
- cyano;
- nitro;
- a carbocyclic or heterocyclic group having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R^9; and
- a group R^a-R^b;

R^a is a bond, O, CO, $X^1C(X^2)$, $C(X^2)X^1$, $X^1C(X^2)X^1$, S, SO, SO_2, NR^c, SO_2NR^c or NR^cSO_2;

R^b is:

- hydrogen;
- a carbocyclic or heterocyclic group having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R^9;
- an acyclic C_{1-12} hydrocarbyl group optionally substituted with one or more substituents selected from hydroxy; oxo; halogen; cyano; nitro; carboxy; amino; mono- or di-C_{1-8} non-aromatic hydrocarbylamino; and carbocyclic or heterocyclic groups having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R^9; wherein one or more but not all of the carbon atoms of the acyclic C_{1-12} hydrocarbyl group may optionally be replaced by O, S, SO, SO_2, NR^c, $X^1C(X^2)$, $C(X^2)X^1$ or $X^1C(X^2)X^1$;

R^c is:

- hydrogen;
- a carbocyclic or heterocyclic group having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S and oxidised forms

thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R^9;

- an acyclic C_{1-12} hydrocarbyl group optionally substituted with one or more substituents selected from hydroxy; oxo; halogen; cyano; nitro; carboxy; amino; mono- or di-C_{1-8} non-aromatic hydrocarbylamino; and carbocyclic or heterocyclic groups having from 3 to 12 ring members, of which 0, 1, 2, 3 or 4 are heteroatom ring members selected from O, N and S and oxidised forms thereof, the carbocyclic or heterocyclic group being optionally substituted with one or more substituents R^9; wherein one or more but not all of the carbon atoms of the acyclic C_{1-12} hydrocarbyl group may optionally be replaced by O, S, SO, SO_2, NH, N-C_{1-4} alkyl, C(O)O, OC(O), NH(CO), C(O)NH, NH(CO)NH, N(C_{1-4} alkyl)C(O), C(O)N(C_{1-4} alkyl)

X^1 is O, S or NR^c; and

X^2 is =O, =S or =NR^c;

wherein R^9 is selected from R^8 provided that when the substituents R^9 contain a carbocyclic or heterocyclic group, the said carbocyclic or heterocyclic group is unsubstituted or substituted with one or more substituents R^{10};

R^{10} is selected from halogen, oxo, cyano, and an acyclic C_{1-6} hydrocarbyl group optionally substituted with one or more substituents selected from hydroxy; oxo; halogen; cyano;carboxy; amino; mono- or di-C_{1-2} alkylamino; wherein one but not all of the carbon atoms of the acyclic C_{1-6} hydrocarbyl group may optionally be replaced by O, S, SO, SO_2, NH or NMe;

R^{11} is selected from amino, Hyd^1, NH-Hyd^1, N(Hyd^1)$_2$; and Cyc^1;

Hyd^1 is a non-aromatic C_{1-6} hydrocarbyl group optionally substituted by one or more substituents selected from halogen, cyano, hydroxy, amino and Cyc^1, wherein one or two of the carbon atoms of the non-aromatic C_{1-6} hydrocarbyl group may optionally be replaced by O, NH, N-Hyd^2, C(=O), S, SO or SO_2, provided that at least one carbon atom of the hydrocarbyl group remains;

Hyd^2 is a C_{1-4} hydrocarbyl group;

and wherein in any group consisting of or containing a hydrocarbyl moiety, the hydrocarbyl moiety is a hydrocarbon group optionally containing one or more single, double or triple carbon-carbon bonds or combinations thereof.

3. A compound according to claim 1 or claim 2 wherein R^1 is selected from hydrogen and methoxy.

4. A compound according to claim 1 wherein R^2 is selected from hydrogen and methoxy.

5. A compound according to claim 1 wherein both of R^3 and R^4 are hydrogen.

6. A compound according to claim 1 wherein R^5 is selected from hydrogen and cyano.

7. A compound according to claim 6 wherein R^5 is cyano.

8. A compound according to claim 1 wherein R^6 is hydrogen.

9. A compound according to claim 1 wherein A is selected from a bond; -NH-CH_2-; -(CH_2)-NH-(CH_2)-; -(CH_2)-NH-(CH_2)-(CH_2)-; -(CH_2)-(CH_2)-NH-(CH_2)-; and -(CH_2)-NH-(CHMe)-.

10. A compound according to claim 1 wherein R^8 is absent or is selected from C_{1-4} hydrocarbyl, C_{1-4}hydrocarbylsulfonyl, oxo, di-C_{1-4}hydrocarbylamino-C_{1-4}alkanoyl, and C_{1-4} hydrocarbylcarbonyl.

11. A compound according to claim 1 wherein R^7 is selected from 4-morpholinyl, 1-methyl-4-piperidinyl and 1-cyclopropylcarbonyl-piperidin-4-yl.

12. A compound according to claim 1 or claim 2 wherein:

R^1 is hydrogen or methoxy;
R^2 is hydrogen or methoxy;
R^3 is hydrogen;
R^4 is hydrogen;
R^5 is hydrogen or cyano;
R^6 is hydrogen;
A is selected from a bond, -NH-CH_2-
; -(CH_2)-NH-(CH_2)-; -(CH_2)-NH-(CH_2)-(CH_2)-; -(CH_2)-(CH_2)-NH-(CH_2)-;
and -(CH_2)-NH-(CHMe)-; and
R^7 is selected from 4-morpholinyl, 1-methyl-4-piperidinyl and 1-cyclopropylcarbonyl-piperidin-4-yl.

13. A compound according to claim 1 or claim 2 wherein:
R^1 is methoxy;
R^2 is hydrogen or methoxy;
R^3 is hydrogen;
R^4 is hydrogen;

R^5 is cyano;

R^6 is hydrogen; and

(i) when A is a bond, R^7 is 1-methyl-4-piperidinyl; or

(ii) when A is -(CH_2)-NH-(CH_2)-, R^7 is 1-cyclopropylcarbonyl-piperidin-4-yl; or

(iii) when A is (CH_2)-NH-(CH_2)-(CH_2)-, R^7 is 4-morpholinyl.

14. A compound according to claim 1 or claim 2 which is selected from:

5-(5-{2-methoxy-4-[(2-morpholin-4-yl-ethylamino)-methyl]-phenyl}-1H-pyrazol-3-ylamino)-pyrazine-2-carbonitrile;

(5-{2-methoxy-4-[(2-morpholin-4-yl-ethylamino)-methyl]-phenyl}-1H-pyrazol-3-yl)-pyrazin-2-yl-amine;

5-{5-[2-methoxy-4-(1-methyl-piperidin-4-yl)-phenyl]-1H-pyrazol-3-ylamino}-pyrazine-2-carbonitrile;

5-[5-(4-{[(1-cyclopropane-carbonyl-piperidin-4-ylmethyl)-amino]-methyl}-2-methoxy-phenyl)-1H-pyrazol-3-ylamino]-pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[(tetrahydropyran-4-ylamino)methyl]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[[methyl(2-morpholinoethyl)amino]methyl]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-(2-morpholinoethylamino)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[1-[2-(dimethylamino)acetyl]-4-piperidyl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[[[(1R)-1-methyl-2-morpholino-ethyl]amino]methyl]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[[(1,1-dimethyl-2-morpholino-ethyl)amino]methyl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-(4-piperidyl)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-fluoro-4-(1-methyl-4-piperidyl)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-(4-methyl-1,4-diazepan-1-yl)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

N-[5-[2-methoxy-4-(1-methyl-4-piperidyl)phenyl]-1H-pyrazol-3-yl]-5-methyl-pyrazin-2-amine;

5-[[5-[4-(1-methyl-4-piperidyl)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[(1-methyl-4-piperidyl)oxy]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[(1-methyl-4-piperidyl)methoxy]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[5-fluoro-2-methoxy-4-(1-methyl-4-piperidyl)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[(3S)-pyrrolidin-3-yl]oxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-(pyrrolidin-2-ylmethoxy)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[(1-methylpyrrolidin-2-yl)methoxy]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-(4-piperidylmethoxy)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[[(1-methyl-4-piperidyl)amino]methyl]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-isopropoxy-4-(1-methyl-4-piperidyl)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-(3-piperidyl)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-(1-methyl-3-piperidyl)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-(1-methyl-2-piperidyl)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[(3S)-1-methylpyrrolidin-3-yl]oxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-chloro-N-[5-[2-methoxy-4-(4-piperidyl)phenyl]-1H-pyrazol-3-yl]pyrazin-2-amine;

5-chloro-N-[5-[2-methoxy-4-(1-methyl-4-piperidyl)phenyl]-1H-pyrazol-3-yl]pyrazin-2-amine;

5-[[5-(2-methoxy-4-piperazin-1-yl-phenyl)-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(2S,6S)-2,6-dimethyl-4-piperidyl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-(2-methoxy-4-tetrahydropyran-4-yl-phenyl)-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-fluoro-4-(4-piperidyl)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-isopropoxy-4-(4-piperidyl)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-(1,4-diazepan-1-yl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

N-[5-[2-methoxy-4-(4-piperidyl)phenyl]-1H-pyrazol-3-yl]-5-methyl-pyrazin-2-amine;

5-[[5-[4-(4-piperidyl)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-(4-piperidyloxy)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[5-fluoro-2-methoxy-4-(4-piperidyl)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-(1-ethyl-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-(1-isopropyl-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

2-[4-[4-[3-[(5-cyanopyrazin-2-yl)amino]-1H-pyrazol-5-yl]-3-methoxy-phenyl]-1-piperidyl]acetamide;

5-[[5-[2-methoxy-4-[[methyl(tetrahydropyran-4-yl)amino]methyl]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-(4-fluoro-1-methyl-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-(1-methylazetidin-3-yl)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-(3-fluoro-1-methyl-azetidin-3-yl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[5-chloro-2-methoxy-4-(1-methyl-4-piperidyl)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[5-chloro-2-methoxy-4-(4-piperidyl)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[3-chloro-2-methoxy-4-(1-methyl-4-piperidyl)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[3-chloro-2-methoxy-4-(4-piperidyl)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[(tetrahydrofuran-3-ylamino)methyl]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[[methyl(tetrahydrofuran-3-yl)amino]methyl]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-(tetrahydropyran-4-ylmethylamino)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-(tetrahydropyran-4-ylmethoxy)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-(4-fluoro-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-(3-fluoroazetidin-3-yl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[(3R)-1-methylpyrrolidin-3-yl]oxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-(2-methoxy-4-morpholino-phenyl)-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-(4-ethylpiperazin-1-yl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;;

5-[[5-[4-(4-isopropylpiperazin-1-yl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[(3R)-3-methylpiperazin-1-yl]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-(4-ethyl-1,4-diazepan-1-yl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-(4-isopropyl-1,4-diazepan-1-yl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-(1-ethyl-4-fluoro-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-(4-fluoro-1-isopropyl-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-(1-ethyl-3-fluoro-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-(3-fluoro-1-isopropyl-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[1-(2-methoxyethyl)-4-piperidyl]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(3R)-3,4-dimethylpiperazin-1-yl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(3R)-4-ethyl-3-methyl-piperazin-1-yl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(3S)-1-isopropylpyrrolidin-3-yl]oxy-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(3R)-1-isopropylpyrrolidin-3-yl]oxy-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(3(R,S),4(R,S))-3-fluoro-1-methyl-4-piperidyl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-(3,3-difluoro-1-methyl-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-(1-ethyl-3,3-difluoro-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[1-(2-hydroxyethyl)-4-piperidyl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-(pyrrolidin-1-ylmethyl)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-(morpholinomethyl)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[[(2R)-1-methylpyrrolidin-2-yl]methoxy]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile hydrochloride;

5-[[5-[2-methoxy-4-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile hydrochloride;

5-[[5-[4-[1-(2-fluoroethyl)-4-piperidyl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[(1-methyl-4-piperidyl)methylamino]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(1-ethyl-4-piperidyl)methylamino]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(1-isopropyl-4-piperidyl)methylamino]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[(1-methyl-4-piperidyl)amino]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(1-ethyl-4-piperidyl)amino]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(1-isopropyl-4-piperidyl)amino]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[(1-methyl-4-piperidyl)oxymethyl]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(1-ethyl-4-piperidyl)oxymethyl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(1-isopropyl-4-piperidyl)oxymethyl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-(2-fluoro-6-methoxy-4-piperazin-1-yl-phenyl)-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[(2R)-4-methylmorpholin-2-yl]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[(2R)-4-ethylmorpholin-2-yl]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[(2S)-4-methylmorpholin-2-yl]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[(2S)-4-ethylmorpholin-2-yl]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-(2,6-dimethoxy-4-piperazin-1-yl-phenyl)-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2,6-dimethoxy-4-(4-methylpiperazin-1-yl)phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[[(3R)-3-fluoropyrrolidin-1-yl]methyl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[[(3S)-3-methoxypyrrolidin-1-yl]methyl]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[[(3R)-3-methoxypyrrolidin-1-yl]methyl]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[[(2R)-1-ethylpyrrolidin-2-yl]methoxy]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[[(2R)-1-isopropylpyrrolidin-2-yl]methoxy]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[[(2S)-1-ethylpyrrolidin-2-yl]methoxy]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[[(2S)-1-isopropylpyrrolidin-2-yl]methoxy]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(cyclopropylmethylamino) methyl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[[[(3R)-tetrahydrofuran-3-yl]amino]methyl]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[[[(3S)-tetrahydrofuran-3-yl]amino]methyl]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(3R)-4-isopropyl-3-methyl-piperazin-1-yl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(1-ethyl-4-piperidyl)oxy]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(1-isopropyl-4-piperidyl)oxy]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-(4-ethylpiperazin-1-yl)-2-fluoro-6-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-(4-isopropylpiperazin-1-yl)-2-fluoro-6-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[[(3S)-1-ethylpyrrolidin-3-yl]oxymethyl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[[(3S)-1-isopropylpyrrolidin-3-yl]oxymethyl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[[(3R)-1-ethylpyrrolidin-3-yl]oxymethyl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[[(3R)-1-isopropylpyrrolidin-3-yl]oxymethyl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-(4-isobutylpiperazin-1-yl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(1-ethyl-4-piperidyl)methyl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(1-isopropyl-4-piperidyl)methyl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(1-ethyl-4-piperidyl)methyl-methyl-amino]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(2R)-4-isopropylmorpholin-2-yl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(1-isopropyl-4-piperidyl)methyl-methyl-amino]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[[(2R)-1-ethylpyrrolidin-2-yl]methyl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(2S)-4-isopropylmorpholin-2-yl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[[(2R)-1-isopropylpyrrolidin-2-yl]methyl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-(2-methoxy-4-piperazin-1-yl-phenyl)-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[[(2S)-1-isopropylpyrrolidin-2-yl]methyl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[[(3S)-1-isopropylpyrrolidin-3-yl]amino]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[[(3R)-1-isopropylpyrrolidin-3-yl]amino]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[[(3R)-1-ethylpyrrolidin-3-yl]amino]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[[(3S)-1-ethylpyrrolidin-3-yl]amino]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[2-methoxy-4-[(3S)-3-methylpiperazin-1-yl]phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(3R)-3-ethylpiperazin-1-yl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(3S)-3-isopropylpiperazin-1-yl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-[(3R)-3-isopropylpiperazin-1-yl]-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

5-[[5-[4-(3,3-dimethylpiperazin-1-yl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile;

and salts and tautomers thereof.

15. A pharmaceutical composition comprising a compound as defined in claim 1 and a pharmaceutically acceptable excipient.

16. A combination comprising a compound as defined in claim 1 and another chemotherapeutic agent.

17. Use of a compound as defined in claim 1, in combination with another chemotherapeutic agent in the manufacture of a medicament for the treatment of a proliferative disease.

18. The compound according to claim 14, wherein the compound is 5-[[5-[4-(4-fluoro-1-methyl-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile or a salt thereof.

19. The compound according to claim 14, wherein the compound is 5-[[5-[4-(4-isopropylpiperazin-1-yl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile or a salt thereof.

20. The compound according to claim 14, wherein the compound is 5-[[5-[4-(4-ethylpiperazin-1-yl)-2-fluoro-6-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile or a salt thereof.